JP2010526813A5 - - Google Patents

Download PDF

Info

Publication number
JP2010526813A5
JP2010526813A5 JP2010507482A JP2010507482A JP2010526813A5 JP 2010526813 A5 JP2010526813 A5 JP 2010526813A5 JP 2010507482 A JP2010507482 A JP 2010507482A JP 2010507482 A JP2010507482 A JP 2010507482A JP 2010526813 A5 JP2010526813 A5 JP 2010526813A5
Authority
JP
Japan
Prior art keywords
alkyl
independently
here
compound
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010507482A
Other languages
English (en)
Japanese (ja)
Other versions
JP5782586B2 (ja
JP2010526813A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/006015 external-priority patent/WO2008140792A1/en
Publication of JP2010526813A publication Critical patent/JP2010526813A/ja
Publication of JP2010526813A5 publication Critical patent/JP2010526813A5/ja
Application granted granted Critical
Publication of JP5782586B2 publication Critical patent/JP5782586B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010507482A 2007-05-10 2008-05-09 フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用 Active JP5782586B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US92859207P 2007-05-10 2007-05-10
US60/928,592 2007-05-10
US99915307P 2007-10-15 2007-10-15
US60/999,153 2007-10-15
PCT/US2008/006015 WO2008140792A1 (en) 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014066444A Division JP6352017B2 (ja) 2007-05-10 2014-03-27 フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用

Publications (3)

Publication Number Publication Date
JP2010526813A JP2010526813A (ja) 2010-08-05
JP2010526813A5 true JP2010526813A5 (enExample) 2011-06-23
JP5782586B2 JP5782586B2 (ja) 2015-09-24

Family

ID=40002552

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010507482A Active JP5782586B2 (ja) 2007-05-10 2008-05-09 フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用
JP2014066444A Active JP6352017B2 (ja) 2007-05-10 2014-03-27 フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014066444A Active JP6352017B2 (ja) 2007-05-10 2014-03-27 フルオレン、アントラセン、キサンテン、ジベンゾスベロン、及びアクリジンの誘導体、並びに、それらの使用

Country Status (17)

Country Link
US (3) US8129519B2 (enExample)
EP (1) EP2152258B1 (enExample)
JP (2) JP5782586B2 (enExample)
KR (1) KR101486026B1 (enExample)
CN (2) CN108314663B (enExample)
AU (1) AU2008251800B2 (enExample)
CA (2) CA2871493C (enExample)
DK (1) DK2152258T3 (enExample)
ES (1) ES2584188T3 (enExample)
HU (1) HUE029155T2 (enExample)
IL (2) IL202039A (enExample)
MX (2) MX2009011970A (enExample)
NZ (2) NZ597731A (enExample)
PL (1) PL2152258T3 (enExample)
PT (1) PT2152258T (enExample)
WO (1) WO2008140792A1 (enExample)
ZA (1) ZA200907859B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871493C (en) * 2007-05-10 2017-03-28 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
US8466149B2 (en) * 2007-08-15 2013-06-18 Merck Sharp & Dohme Corp. 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I
WO2011019651A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
KR101161290B1 (ko) 2009-10-16 2012-07-02 에스에프씨 주식회사 축합방향족화합물 및 이를 이용한 유기전계발광소자
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
EP3473099A1 (en) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
AU2012332111B2 (en) * 2011-11-06 2016-11-17 Beta Cat Pharmaceuticals, Llc Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ629282A (en) 2012-05-04 2017-04-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
CA2897400A1 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
AU2015334842B2 (en) * 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US9725473B2 (en) * 2015-07-28 2017-08-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017058716A1 (en) * 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
JP6982748B2 (ja) 2015-11-06 2021-12-17 バイオスプライス セラピューティクス インコーポレイテッド 2−(1H−インダゾール−3−イル)−3H−イミダゾ[4,5−c]ピリジンおよびそれらの抗炎症的使用
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
SI3464285T1 (sl) 2016-06-01 2023-02-28 Biosplice Therapeutics, Inc. Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
CN106106481B (zh) * 2016-06-16 2019-06-28 湖北工业大学 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法
KR102593742B1 (ko) 2016-10-21 2023-10-24 사뮤메드, 엘엘씨 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도
JP7630905B2 (ja) 2016-11-07 2025-02-18 バイオスプライス セラピューティクス インコーポレイテッド 単回用量の調整済み注射用製剤
WO2018118711A1 (en) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
CA3101994A1 (en) * 2018-06-01 2019-12-05 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof
US11571388B2 (en) 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint
CN117567385B (zh) * 2023-11-23 2024-04-30 中国人民解放军军事科学院军事医学研究院 一种靶向clec5a的小分子抑制剂及其应用
CN119409635A (zh) * 2024-11-04 2025-02-11 河南师范大学 具有抗癌活性的氟代甲基取代茚并[1,2-b]吡啶类化合物及其合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627791A (en) * 1968-11-21 1971-12-14 Richardson Merrell Inc Bis(aminoalkylsulfamoyl) anthraquinones
US3983248A (en) 1968-11-21 1976-09-28 Richardson-Merrell Inc. Bis(aminoalkylsulfamoyl)anthraquinone antiviral agents
US3829578A (en) * 1970-12-10 1974-08-13 Richardson Merrell Inc Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith
US3714194A (en) * 1971-06-09 1973-01-30 Upjohn Co Di(azidosulfonyl)xanthones
US3919211A (en) * 1973-02-12 1975-11-11 American Home Prod 9-Oxoxanthene-N,N{40 -bis(substituted)-2,7-disulfonamides
US3981248A (en) * 1975-02-28 1976-09-21 Hall Ski-Lift Company, Inc. Timing gate for ski-lifts
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications
US4276224A (en) * 1978-06-07 1981-06-30 Ciba-Geigy Corporation Anthraquinone sulphonamide compounds and preparation
DE3044072A1 (de) * 1980-11-24 1982-07-15 Hoechst Ag, 6000 Frankfurt Bis-aminomehtyl-anthrachinon-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
IT1223302B (it) 1987-09-16 1990-09-19 Baldacci Lab Spa Composti solfonamido derivati inibitori del sistema enzimatico aldoso-reduttasi e composizioni farmaceutiche che li contengono
HUT67314A (en) * 1993-04-09 1995-03-28 Egyt Gyogyszervegyeszeti Gyar Process for prepg. new trisubstituted cykloalkane deriv.s and pharmaceutical compn.s contg. them
AU2001269291A1 (en) * 2000-07-07 2002-02-05 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
WO2002011574A1 (en) * 2000-08-10 2002-02-14 Benetton Group S.P.A. Sports shoe
CA2473170A1 (en) * 2002-01-15 2003-07-24 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
US6693136B1 (en) * 2002-07-26 2004-02-17 Abbott Laboratories Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
CA2871493C (en) * 2007-05-10 2017-03-28 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Similar Documents

Publication Publication Date Title
JP2010526813A5 (enExample)
JP2009516727A5 (enExample)
JP2013147496A5 (ja) 有機金属錯体
WO2009010660A3 (fr) Indazoles substitues, leur preparation et leur utilisation en therapeutique
JP2011528706A5 (enExample)
WO2006039668B1 (en) 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis c infection
TW200730514A (en) Morpholine type cinnamide compound
TW200738706A (en) Pyrido-, pyrazo-and pyrimido-pyrimidine derivatives and their use as mTOR inhibitors
WO2007060257A3 (en) Diketopyrrolo-pyrrole compounds
ATE556058T1 (de) 1-(2h)-isochinolonderivat
PH12012501773A1 (en) Arylethynyl derivatives
JP2007508362A5 (enExample)
JP2010527915A5 (enExample)
JP2012520247A5 (enExample)
CY1114932T1 (el) Αντιπαρασιτικοι παραγοντες
JP2013510178A5 (enExample)
JP2010529961A5 (enExample)
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
MX2012008372A (es) Derivado de imidazol sustituido con cicloalquilo.
CY1111642T1 (el) Παραγωγα διυδροπυριδινων
JPWO2020054788A5 (enExample)
AR067937A1 (es) Derivados de indol -2- ona disustituidos en 3, su preparacion y su aplicacion en terapeutica
JP2008501649A5 (enExample)
JP2017521489A5 (enExample)
MY165141A (en) Pyrazolidin-3-one derivatives